SCHEDULE: Tactic Pharma Exits Monopar Therapeutics Stake

Tactic Pharma LLC and its principals have ceased to be beneficial owners of more than five percent of Monopar Therapeutics common stock following a pro rata distribution to its members.

Summary

• Tactic Pharma LLC, Chandler Robinson, and Michael Brown (the "Reporting Persons") are filing Amendment No. 3 to their Schedule 13D, which serves as a final amendment and exit filing.
• On January 28, 2026, Tactic Pharma LLC completed a liquidating, pro rata distribution of its holdings in Monopar Therapeutics' Common Stock to its members.
• As a direct result of this distribution, as of January 28, 2026, each of the Reporting Persons ceased to be a beneficial owner of more than five percent of Monopar Therapeutics' Common Stock.
• The percentages of ownership are calculated based on 6,682,584 shares of Common Stock outstanding, as reported in Monopar Therapeutics' Form 10-Q for the quarter ended September 30, 2025.
• Post-distribution, Tactic Pharma LLC holds 0.00 shares, representing 0.0% of the class.
• Chandler Robinson beneficially owns 307,370 shares, or 4.5% of the class, which includes 6,732 restricted stock units vesting within 60 days and 152,105 stock options exercisable within 60 days.
• Michael J Brown beneficially owns 124,629 shares, or 1.8% of the class, including 18,878 stock options.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event for Monopar Therapeutics, primarily reflecting a change in the ownership structure of the Reporting Persons rather than a direct positive or negative operational development for the company.

Future Outlook

No forward-looking statements or guidance are provided in this filing.

Industry Context

StockSavvy.ai notes that the exit of a significant institutional holder like Tactic Pharma, while not necessarily indicative of operational issues for Monopar Therapeutics, can sometimes lead to increased trading volume or short-term price volatility as distributed shares enter the market. This type of ownership change is common in the lifecycle of early-stage investments.

Stakeholder Impact

• Shareholders: Existing shareholders of Monopar Therapeutics may experience increased liquidity or potential short-term price fluctuations as shares previously held by Tactic Pharma are distributed and potentially traded.
• Reporting Persons: Tactic Pharma LLC has completed its liquidation and distribution of Monopar shares, effectively exiting its beneficial ownership position. Chandler Robinson and Michael Brown now hold less than 5% individually.

Next Steps

• The filing states that this Amendment No. 3 represents the final amendment to the Schedule 13D and constitutes an exit filing for the Reporting Persons, indicating no further actions from these specific reporting persons under this Schedule 13D.

Key Dates

Keywords

Monopar Therapeutics, Tactic Pharma, Schedule 13D, Beneficial Ownership, Stock Distribution, Exit Filing, Common Stock, SEC Filing, Shareholder Change